World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
69015
World Ranking
5420
National Ranking
535

Mahesh K. B. Parmar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mahesh K. B. Parmar sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 429 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mahesh K. B. Parmar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mahesh K. B. Parmar sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mahesh K. B. Parmar is affiliated with University College London in the United Kingdom, focusing primarily on medical research. Their work spans several main fields and subfields, indicating a concentration on areas related to oncology and clinical trials.

The main field of study associated with Parmar's work is Medicine, with a total of 231 publications. Within this broad field, their subfields of study include:

  • Pulmonary and Respiratory Medicine (85 publications)
  • Statistics and Probability (52 publications)
  • Oncology (34 publications)
  • Radiology, Nuclear Medicine and Imaging (22 publications)
  • Reproductive Medicine (19 publications)

Parmar has explored various key topics in their research, notably:

  • Prostate Cancer Treatment and Research (88 publications)
  • Statistical Methods in Clinical Trials (66 publications)
  • Prostate Cancer Diagnosis and Treatment (42 publications)
  • Ovarian cancer diagnosis and treatment (32 publications)
  • Health Systems, Economic Evaluations, Quality of Life (30 publications)
  • Cancer Genomics and Diagnostics (24 publications)
  • Radiopharmaceutical Chemistry and Applications (22 publications)

Their recent publications include the following works, which have appeared in established medical journals:

  • "Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial," 2021, The Lancet
  • "A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19," 2020, New England Journal of Medicine
  • "Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial," 2020, The Lancet
  • "Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data," 2020, The Lancet
  • "Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis," 2021, The Lancet Regional Health - Europe

Frequent co-authors collaborating with Parmar include:

  • Matthew R. Sydes (46 joint publications)
  • Noel W. Clarke (43 joint publications)
  • Nicholas D. James (39 joint publications)
  • Gerhardt Attard (26 joint publications)
  • Adrian Cook (19 joint publications)

The primary publication venues for Parmar's work are journals that focus on oncology and clinical trial research. These include:

  • Journal of Clinical Oncology (15 publications)
  • The Lancet Oncology (9 publications)
  • Annals of Oncology (9 publications)
  • Trials (7 publications)
  • Clinical Trials (7 publications)

Best Publications

  • Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

    Mahesh K. B. Parmar;Valter Torri;Lesley Stewart

  • Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

    Hashim U Ahmed;Hashim U Ahmed;Ahmed El-Shater Bosaily;Ahmed El-Shater Bosaily;Louise C. Brown;Rhian Gabe

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

    David Sebag-Montefiore;Richard J. Stephens;Robert Steele;John Monson

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

    Patrick Royston;Mahesh K. B. Parmar

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

    Phil Quirke;Phil Quirke;Robert Steele;John Monson;Robert Grieve

  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

    Sean Kehoe;Jane Hook;Matthew Nankivell;Gordon C Jayson

  • Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

    Ian J Jacobs;Ian J Jacobs;Ian J Jacobs;Usha Menon;Andy Ryan;Aleksandra Gentry-Maharaj

  • International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

    Gareth Griffiths;Reginald Hall;Richard Sylvester;Derek Raghavan

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

    Patrick Royston;Mahesh K B Parmar

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials

    Claire Vale;Jayne F. Tierney;Lesley A. Stewart;Mark Brady

  • Survival Analysis: A Practical Approach

    David Machin;Yin Bun Cheung;Mahesh K. B. Parmar

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

    Michele Saunders;Stanley Dische;Ann Barrett;Angela Harvey

  • Bayesian Approaches to Randomized Trials

    David J. Spiegelhalter;Laurence S. Freedman;Mahesh K. B. Parmar

  • Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

    Usha Menon;Aleksandra Gentry-Maharaj;Rachel Hallett;Andy Ryan

Frequent Co-Authors

Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Malcolm David Mason
Malcolm David Mason Cardiff University
Ian Jacobs
Ian Jacobs University of New South Wales
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Patrick Royston
Patrick Royston University College London
Chris Parker
Chris Parker Institute of Cancer Research
Usha Menon
Usha Menon University College London
Stephen W. Duffy
Stephen W. Duffy Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA isn’t limited to becoming a doctor—numerous online degree pathways are available for those seeking flexible options. Registered nurses can upgrade their credentials through rn to bsn programs, which often offer coursework with minimal or no on-site clinical requirements, making them accessible for working professionals.

Those aiming for leadership or advanced practice roles may consider pursuing the shortest dnp programs online, which provide a compact curriculum focused on quick completion. There are even shortest dnp program options designed for efficiency, ideal for nurses eager to achieve a terminal degree without a lengthy time commitment.

For individuals starting their careers, fast track medical programs such as Licensed Practical Nurse (LPN) routes enable entry into the healthcare workforce in less time—using a flexible online format. These related pathways provide modern, efficient alternatives for advancing or starting a medical career in the USA.

Best Scientists Citing Mahesh K. B. Parmar

Trending Scientists